Reckitt buys Paras for $726 million

Reckitt Benckiser has bought Paras Pharmaceuticals for Rs32.6 billion ($726 million) from its shareholders, which include the founding family, the Patels, and private-equity firms Actis and Sequoia. The deal captures the dual trends of consolidation in the consumer space in Asia and private-equity firms exiting investments, which have characterised this year.